Article info
PDFClinicopathological conference
Visual loss with chronic meningeal and systemic inflammation
- Correspondence to Dr Peter M Fernandes, Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh EH8 9YL, UK; peter.fernandes{at}ed.ac.uk
Citation
Visual loss with chronic meningeal and systemic inflammation
Publication history
- Accepted June 18, 2021
- First published August 13, 2021.
Online issue publication
January 20, 2022
Article Versions
- Previous version (20 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)
- Cryopyrin-associated periodic syndrome: a treatable genetic inflammatory condition
- Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features
- Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry
- Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry
- Autoinflammatory syndromes in neurology: when our first line of defence misbehaves
- Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6–10 November 2005
- The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist
- Cutaneous signs and mechanisms of inflammasomopathies
- Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes